Presenter's Information

Roxana Mehran, MD

Country USA
Specialty Interventional Cardiologist
  1. SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus
  2. Factor XI Inhibitors in Availalbe RCTs: A Meta-analysis and Future Perspectives
  3. An Individualized Patient-Centered Machine Learning for Prediction of Ischemic and Bleeding Risk after PCI
  4. What Are Novel and Future Antithrombotic Drugs in ACS and PCI? Are There Still Unmet Needs?
  5. Next Novel Antithrombotic Drugs for ACS/PCI: Oral Factor XIa inhibitor or More
  6. Year-In-Review: Interventional Pharmacology
  7. Optimal DAPT Duration for PCI Patients at High Beeding Risk
  8. Potent P2Y12 Inhibitors for East-Asian Patients: Insights from the TWIGHLIGHT in Western vs. Asian Population
  9. Interventional Pharmacology Year-In-Review
  10. Aspirin Plus NOAC Will Be the Standard of Care.
  11. HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-based DES with a Luminal CD34+ Antibody Coating Versus a Durable Polymer-based DES in Patients with Coronary Artery Disease
  12. Optimal Balancing Ischemic and Bleeding Risks in Contemporary PCI Practice: TWILIGHT, GLOBAL-LEADER and More...
  13. Optimal Initiation and Duration of DAPT in ACS Patient; Reviewing the Evidence of Ticagrelor
  14. Pretreatment with P2Y12 Inhibitors in NSTE-ACS: Selective vs. Routine?
  15. EPC Capture Stent : A Promising Solution Amongst the DAPT Controversy?
  16. The DAPT Debate - 2016
  17. Upcoming Trend in ACS Patient Management
  18. The DAPT Duration Debate - Practical Synthesis and Clinical Recommendations
  19. Vulnerable Plaque Is a Systemic Disease: Insights from BioImage
  20. Revisiting Anticoagulants: Why Dual Pathway Inhibition Is Not Back?
  21. Optimal DAPT Duration for Current and Future DES and BVS
  22. Will Long Term Dual Antiplatelet Therapy Improve LT Outcome?
  23. Does True Vessel Healing Matter?
  24. Interventional Pharmacology - Year in Review 
  25. No Benefits, Possible Harms - The ACCOAST Trial
  26. The Next Era: COMBO Dual Therapy Stent
  27. [Bivalirudin: Is It Standard of Care in the Cath Lab?] No, Heparin with Provisional GPI Is Still a Viable Option.
  28. Surveying the Landscape of New Anti-platelet Agents: A Practical User’s Guide
  29. Update on Left Main/Multivessel PCI: Lessons from SYNTAX, a View to EXCEL
  30. Impact of Bleeding and Tailored or Personalized Antiplatlet Therapy to Reduce Bleeding in ACS or PCI Patients: From Clopidogrel to Prasugrel and Ticagrelor
  31. Bleeding & Mortality: Beyond the Horizon
  32. The NEW Anti-platelet Agents and Platelet Reactivity Testing: Recommendations for Prasugrel and Ticagrelor and Lessons from GRAVATAS
  33. Behind Closed Doors: Functions of a Data Safety Monitoring Board
  34. Types of Clinical Trials in Cardiology: The Rationale for Trial Design
  35. PCI in Chronic Kidney Disease (RECOVER, CARE, LOCM-Related Studies, and Meta-Analysis)
  36. Parenteral Anticoagulants Use in ACS (HORIZONS-AMI, and SEPIA-ACS Trial)
  37. The Role of New Anti-platelet Agents: Will Prasugrel and Ticagrelor Change the DES Landscape?
  38. Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib
  39. New Paradigms in Treatment of ACS/AMI
  40. Quality Control of Clinical Trials: Blinding, Clinical Event Committees, Core Labs, and Data Standards
  41. ACS/AMI: What’s Hot, What’s Not!
  42. Impact of Ischemic vs. Bleeding Endpoints: Lessons from ACUITY and HORIZONS
  43. The Impact of Hemorrhagic Complications on PCI Outcomes: Lessons from ACUITY, HORIZONS and Other Trials
  44. TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI
  45. In-Stent Restenosis
  46. HORIZONS AMI: Bivalirudin vs. Unfractionated Heparin plus GPIIb/IIIa Inhibitors in STEMI
  47. The Interventional Trials of the Year: 2007-2008 (TCT, AHA, and ACC)
  48. The CoStar Clinical Data
  49. ACUITY: One Year Outcome of ACUITY Trial
  50. Renal Failure and Contrast Nephropathy: An Overview and Considerations in the PCI Patient
  51. The Interventional Trials of the Year: 2006-2007 (TCT, AHA, and ACC)
  52. Complications Related to the Use of Radiocontrast Agents
  53. A Prospective "All Comers" CYPHER Nonrandomized Registry in Complex Patients From MATRIX
  54. Revised Protocol of COMBAT(Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease)
  55. Radiocontrast Nephropathy: Still the Achilles' Heel of Interventional Cardiology
  56. Countdown to COMBAT
Conference Slides
Category